These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 24433338)

  • 1. A new frontier in haematology - combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drug.
    Arpon DR; Gandhi MK; Martin JH
    Br J Clin Pharmacol; 2014 Aug; 78(2):274-81. PubMed ID: 24433338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of pharmacokinetic studies for patients with gastrointestinal stromal tumors.
    De Giorgi U
    Future Oncol; 2013 Nov; 9(11):1675-7. PubMed ID: 23862700
    [No Abstract]   [Full Text] [Related]  

  • 3. Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia.
    Golabchifar AA; Rezaee S; Ghavamzadeh A; Alimoghaddam K; Dinan NM; Rouini MR
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):85-93. PubMed ID: 24817601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Old disease, new targets. Part-II, haematological malignancies.
    Kumar S; Masood N; Adil SN
    J Pak Med Assoc; 2009 Aug; 59(8):555-61. PubMed ID: 19757705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for therapeutic drug monitoring of targeted anticancer therapies.
    Gao B; Yeap S; Clements A; Balakrishnar B; Wong M; Gurney H
    J Clin Oncol; 2012 Nov; 30(32):4017-25. PubMed ID: 22927532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib mesylate in the treatment of hematologic malignancies.
    Piccaluga PP; Rondoni M; Paolini S; Rosti G; Martinelli G; Baccarani M
    Expert Opin Biol Ther; 2007 Oct; 7(10):1597-611. PubMed ID: 17916051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacokinetic issues on cancer pharmacotherapy].
    Tanigawara Y
    Nihon Rinsho; 2015 Aug; 73(8):1357-63. PubMed ID: 26281690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.
    Gotta V; Widmer N; Decosterd LA; Chalandon Y; Heim D; Gregor M; Benz R; Leoncini-Franscini L; Baerlocher GM; Duchosal MA; Csajka C; Buclin T
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1307-19. PubMed ID: 25297989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors.
    Yoo C; Ryu MH; Ryoo BY; Beck MY; Kang YK
    Invest New Drugs; 2013 Oct; 31(5):1367-74. PubMed ID: 23591629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.
    Wilson J; Connock M; Song F; Yao G; Fry-Smith A; Raftery J; Peake D
    Health Technol Assess; 2005 Jul; 9(25):1-142. PubMed ID: 15985189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory.
    Bouchet S; Titier K; Moore N; Lassalle R; Ambrosino B; Poulette S; Schuld P; Belanger C; Mahon FX; Molimard M
    Fundam Clin Pharmacol; 2013 Dec; 27(6):690-7. PubMed ID: 23113675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Existence of leukemic clones resistant to both imatinib mesylate and rituximab before drug therapies in a patient with Philadelphia chromosome-positive acute lymphocytic leukemia.
    Hato T; Yamanouchi J; Tamura T; Hojo N; Niiya Y; Kohno M; Bando S; Yakushijin Y; Takada K; Sakai I; Yasukawa M; Fujita S
    Int J Hematol; 2004 Jul; 80(1):62-6. PubMed ID: 15293570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
    Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic molecular marker and molecular targeted-therapy in pediatric malignancies].
    Hayashi Y
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):194-202. PubMed ID: 17301526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer.
    Kelley RK; Hwang J; Magbanua MJ; Watt L; Beumer JH; Christner SM; Baruchel S; Wu B; Fong L; Yeh BM; Moore AP; Ko AH; Korn WM; Rajpal S; Park JW; Tempero MA; Venook AP; Bergsland EK
    Br J Cancer; 2013 Oct; 109(7):1725-34. PubMed ID: 24022191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review of population pharmacokinetic analyses of imatinib and relationships with treatment outcomes.
    Gotta V; Buclin T; Csajka C; Widmer N
    Ther Drug Monit; 2013 Apr; 35(2):150-67. PubMed ID: 23503441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring of imatinib targeted delivery in human leukocytes.
    Kralj E; Žakelj S; Trontelj J; Pajič T; Preložnik Zupan I; Černelč P; Ostanek B; Marc J; Kristl A
    Eur J Pharm Sci; 2013 Sep; 50(1):123-9. PubMed ID: 23643738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular target therapy for malignant tumors].
    Nihon Naika Gakkai Zasshi; 2005 Feb; 94 Suppl():76-80. PubMed ID: 15796061
    [No Abstract]   [Full Text] [Related]  

  • 19. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-dose, randomized crossover comparisons of different-strength imatinib mesylate formulations in healthy Korean male subjects.
    Kim KA; Park SJ; Kim C; Park JY
    Clin Ther; 2013 Oct; 35(10):1595-602. PubMed ID: 24060561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.